Sarepta Therapeutics (SRPT) Cash & Current Investments (2010 - 2026)

Sarepta Therapeutics has reported Cash & Current Investments for 17 years, with the latest figure at $685.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments rose 31.04% year-over-year to $685.0 million; the trailing twelve-month figure through Mar 2026 stood at $685.0 million (up 31.04% YoY), and the FY2025 full-year result was $853.0 million, down 37.04% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $685.0 million, down from $853.0 million in the prior quarter.
• The five-year high for Cash & Current Investments was $2.1 billion in Q3 2022, with the low at $522.8 million in Q1 2025.
• Average Cash & Current Investments over 5 years is $1.4 billion, with a median of $1.5 billion recorded in 2024.
• Year-over-year, Cash & Current Investments plunged 62.41% in 2025 and soared 31.04% in 2026.
• Tracing SRPT's Cash & Current Investments over 5 years: stood at $2.0 billion in 2022, then declined by 15.74% to $1.7 billion in 2023, then decreased by 19.18% to $1.4 billion in 2024, then slumped by 37.04% to $853.0 million in 2025, then declined by 19.69% to $685.0 million in 2026.
• The last three Cash & Current Investments figures came in at $685.0 million (Q1 2026), $853.0 million (Q4 2025), and $642.5 million (Q3 2025), per Business Quant data.

Peer Comparison